Pharmaceuticals

Xingqi Pharmaceutical

Xingqi Pharmaceutical released FY2026 Q1 earnings on April 27 Pre-Market (BJT), actual revenue CNY 683.34 M, actual EPS CNY 0.84

Xingqi Pharmaceutical to Release FY2026 Q1 Earnings on April 28, Pre-Market BJT

Xingqi Pharmaceutical released FY2025 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 569.12 M, actual EPS CNY 0.3922

Xingqi Pharmaceutical released FY2025 earnings on April 21 After-Market (BJT), actual revenue CNY 2.473 B (forecast CNY 2.68 B), actual EPS CNY 2.83 (forecast CNY 2.7398)

Xingqi Pharmaceutical to Release FY2025 Earnings on April 22 After-Market (BJT), Forecast Revenue CNY 2.68 B, EPS CNY 2.7398

Xingqi Pharmaceutical released FY2025 Q3 earnings on October 28 During-Market BJT, actual revenue CNY 740.99 M, actual EPS CNY 1.0824

Xingqi Pharmaceutical released FY2025 9 Months Earnings on October 28 During-Market (BJT), actual revenue CNY 1.904 B, actual EPS CNY 2.4394

Xingqi Pharmaceutical to Release FY2025 Q3 Earnings on October 29 During-Market (BJT)

Xingqi Pharmaceutical released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 626.6 M, actual EPS CNY 0.767

Xingqi Pharmaceutical released FY2025 Semi-Annual Earnings on August 27 Pre-Market (BJT), Actual Revenue: CNY 1.163 B, Actual EPS: CNY 1.36

Xingqi Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Xingqi Eye Medicine's Voriconazole Eye Drops Enter Phase II Clinical Trials

Xingqi Eye Medicine Completed the First Enrollment for SQ-22031 Eye Drops Phase II Clinical Trial

Huansan Securities' Report Recommends Buying Xingqi Eyedrops

Xingqi Eye Medicine's SQ-22031 Eye Drops are Classified as Innovative Biologics of Category 1

Xingqi Eye Medicine's SQ-22031 Eye Drops Enter Phase II Clinical Trial

Xingqi Eye Medicines Lidocaine Ophthalmic Gel Enters Phase III Clinical Trials

Xingqi Eye Medicine Announces New Equity Offering Plan

Xingqi Eyedrops Plans Financing to Counter Market Competition

Xingqi Eye Medicine's SQ-22031 Drops Pass Phase I Clinical Trial

Capitalization issue

Ex Date: 2026.05.22, Share conversion 4.5 for every 10 shrs held

Ordinary dividend (cash)

Ex Date: 2026.05.22, Cash dividend 1 CNY

300573

Xingqi Pharmaceutical released its Q3 2025 report, with operating revenue for the first three quarters reaching 1.904 billion yuan, a year-on-year increase of 32.27%; net profit attributable to shareholders was 599 million yuan, a year-on-year increase of 105.98%; net profit excluding non-recurring gains and losses was 596 million yuan, a year-on-year increase of 105.76%; basic earnings per share were 2.44 yuan

Zhitong

Xingqi Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 599 million yuan, an increase of 105.98%

Xingqi Pharmaceutical announced that its developed SQ-129 vitreous sustained-release injection has received clinical trial approval from the National Medical Products Administration. This drug is a Class 2 modified new drug aimed at treating diabetic macular edema in adult patients and macular edema caused by retinal branch vein occlusion or central vein occlusion. Studies have shown that this drug has good safety and clinical development value, and currently, there are no similar products approved for market

Xingqi Pharmaceutical: SQ-129 vitreous body sustained-release injection has obtained clinical trial approval

According to the Zhitong Finance APP, Xingqi Pharmaceutical released its semi-annual report for 2025, with operating revenue of 1.163 billion yuan, a year-on-year increase of 30.38%. The net profit attributable to shareholders of the listed company was 335 million yuan, a year-on-year increase of 97.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 331 million yuan, a year-on-year increase of 96.30%. The basic earnings per share were 1.36 yuan

Xingqi Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 335 million yuan, an increase of 97.75%

Xingqi Pharmaceutical announced that in the first half of 2025, operating revenue reached 1.163 billion yuan, a year-on-year increase of 30.38%. Net profit was 335 million yuan, a year-on-year increase of 97.75%. It plans to distribute a cash dividend of 7 yuan for every 10 shares to all shareholders

Xingqi Pharmaceutical: Net profit in the first half of 2025 increased by 97.75% year-on-year, plans to distribute 7 yuan for every 10 shares

According to the Zhitong Finance APP, Xingqi Pharmaceutical announced that the company's developed voriconazole eye drops completed the enrollment of the first subject today, officially entering Phase II clinical trials. The Phase II clinical trial study of voriconazole eye drops is a randomized, positive-controlled, multi-center exploratory trial aimed at preliminarily exploring the efficacy and safety of voriconazole eye drops in subjects with fungal keratitis, in order to explore safe and effective drug concentrations for Phase III clinical trials

Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of Voriconazole eye drops

600671

The ophthalmology concept experienced a volatile rebound, with TMSP hitting the limit up, followed by gains in Xingqi Pharmaceutical, Laimei Pharmaceutical, Nosseland, Daheng Technology, Guanhao Biological, and Doctor Glasses

TMSP

Ophthalmology concept experiences a volatile rebound, TMSP hits the limit up

Xingqi Pharmaceutical announced that its developed SQ-22031 eye drops have completed the enrollment of the first subject and officially entered the Phase II clinical trial for neurotrophic keratitis. The trial is randomized, double-blind, placebo-controlled, and parallel-controlled, and is expected not to have a significant impact on the company's recent performance

Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitis

Xingqi Pharmaceutical announced that its developed lidocaine hydrochloride ophthalmic gel has completed the enrollment of the first subject and officially entered Phase III clinical trials. The trial aims to evaluate the efficacy and safety of the drug in ocular surface anesthesia. Lidocaine hydrochloride is a commonly used local anesthetic that can prolong the contact time of the drug with the ocular surface and improve the anesthetic effect

Xingqi Pharmaceutical: The first subject has been enrolled in the Phase III clinical trial of Lidocaine Hydrochloride Ophthalmic Gel

Xingqi Pharmaceutical announced that its developed SQ-22031 eye drops have obtained the Phase I clinical research report, evaluating its safety, tolerability, and pharmacokinetics in healthy subjects. The indication for this drug is neurotrophic keratitis, and currently, there are no similar drugs approved for market

Xingqi Pharmaceutical: SQ-22031 eye drops obtain Phase I clinical research report

Xingqi Pharmaceutical(300573.SZ)